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Abstract: 
Background: International guideline recommendations for the use of folate and its derivatives 
in the treatment of unipolar depressive disorders are confused and contradictory, perhaps 
reflecting wide variations in the underpinning evidence base. 
Introduction: We discuss differing methods of evidence synthesis in the formulation of 
international guideline recommendations. As an example we evaluated the efficacy of folate 
and its derivatives in unipolar depression via systematic review and meta-analysis. 
Methods: We searched Medline, EMBASE, PsychInfo and CENTRAL from database inception 
until 1st May 2017 for randomised controlled trials. We included trials that evaluated folate 
or its derivatives as monotherapy or to augment antidepressant therapy compared with 
placebo in patients with unipolar depressive illness. Standardised mean differences were used 
and studies were introduced as subgroups to explain the heterogeneity. Quality was assessed 
using the Grading of Recommendations Assessment, Development and Evaluation (GRADE). 
Results: No trials report on folate or methylfolate versus placebo as a monotherapeutic 
option. Only when the evidence was restricted to folate at a dose of <5mg/day or 
methylfolate at a dose of 15mg once daily as an adjunct to SSRI therapy was there a significant 
benefit compared with placebo. All evidence was graded as low or very low quality for each 
outcome.   
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Discussion: Whilst previous guidelines on the treatment of unipolar depression have either 
avoided this topic entirely, or made recommendations on the basis of cherry picked evidence, 
this review is the first to attempt to provide clinically useful recommendations based on 
comprehensive, current randomised placebo-controlled data. We invite discussion of the 
review and its recommendations, which are based on the limited evidence regarding folate 
formulation delivered and appropriate dosage.  
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Introduction: 
International guideline recommendations for the use of folate and its derivatives in the 
treatment of unipolar depressive disorders are confused and contradictory.  Different 
guidelines use evidence from meta-analyses, randomised controlled trials and observational 
studies in inconsistent ways and often reach different conclusions.  
Of the four most commonly cited international guidelines for the treatment of depressive 
illness, (The National Institute for Health and Care Excellence (NICE), The World Federation of 
Societies of Biological Psychiatry (WFSBP), The British Association for Psychopharmacology 
(BAP) and The Canadian Network for Mood and Anxiety Treatments (CANMAT) (NICE, 2016, 
Bauer et al., 2013, Cleare et al., 2015, Patten, 2016) two (NICE and WFSPB) (NICE, 2016, Bauer 
et al., 2013) do not review or comment on the utility of folate or its derivatives as a potential 
treatment.  
One (BAP) (Cleare et al., 2015) does not recommend folate or l-methylfolate as monotherapy 
for major depression, nor does it recommend folate as an adjunctive treatment option. It 
does however recommend l-methylfolate as a potentially effective next-step treatment as an 
adjunct to SSRIs. These recommendations are based on the guideline definition of ‘level II 
evidence’, which states to be from “small, non-replicated, randomised controlled trials, at 
least one controlled study without randomisation or evidence from at least one other type of 
quasi-experimental study”. The narrative explanation of their (BAP) negative 
recommendations with regards to folate therapy are based on the evidence of a single 
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randomised controlled trial, (Bedson et al., 2014) whilst acknowledging the existence of a 
systematic review and meta-analysis of two pooled trials which found ‘folate more effective 
than placebo supplementation of antidepressants’. (Taylor et al., 2003) The BAP guidelines 
basis for positive recommendation of l-methylfolate as an adjunct to SSRIs was based on a 
meta-analysis of two pooled trials. (Papakostas et al., 2012b)  
The remaining guideline (CANMAT) (Patten, 2016) recommends folate as a third line 
adjunctive treatment in mild to moderate major depressive disorder (MDD) based on their 
categorisation of ‘level 2 evidence’ which is stated to be ‘meta-analysis with wide confidence 
intervals and/or 1 or more RCTs with adequate sample size’. The authors state that whilst ‘A 
meta-analysis of folic acid (Almeida et al., 2015) found no evidence to support its efficacy as 
a short-term adjunctive agent for antidepressants, two narrative reviews (Fava and 
Mischoulon, 2009, Papakostas et al., 2012a) and a retrospective observational analysis 
(Ginsberg et al., 2011) support the use of folate preparations (particularly L methylfolate) as 
monotherapy or adjunct to antidepressants for major depressive disorder (MDD).’  
It would be helpful to clinicians for international guidelines to make definitive, or at least 
consistent, recommendations, both positive and negative, for a medicinal product, 
particularly when the evidence base is mixed.  We note that the most recent Cochrane review 
on the topic is dated 2003. (Taylor et al., 2003)  Recommendations or lack thereof on folate 
therapy are inconsistent across international guidance and are based on wide variations in 
the interpretation of the same underpinning evidence base.   
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This critique aims to explore the basis for decision making surrounding these 
recommendations, the utility and correct usage of meta-analyses for decision making and 
explores other evidence based hierarchy structures such as Grading of Recommendations, 
Assessment, Development and Evaluations (GRADE), which may serve as an alternative to the 
traditional ‘level of evidence’ which are granted to certain study designs when formulating 
guideline recommendations.     
In an era of increased focus on clinical trial registration and increased pressure to commit to 
publish negative results, (AllTrials) this review seeks to address what happens when there is 
an increased volume of mixed results in the literature. How might guideline developers 
consolidate this information and articulate it for clinicians who want guidance on what and 
what not to do in practice? 
   
The challenges with systematic review 
One of the main challenges when compiling a systematic review is judgement of the 
consistency between differing studies’ populations, interventions, comparisons and 
outcomes, and therefore the ability of results from different studies to be usefully and 
appropriately combined in meta-analysis. Often critiques and ‘rapid-responses’ to published 
meta-analyses will cite phrases such as ‘this is the combining of apples and oranges’, 
(Ranganathan, 2014) and thus claim the reported meta-analytic results are invalid. There is 
obviously a trade-off between acknowledging clinical diversity within a study sample and 
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inappropriately combining results. This is particularly exemplified in the folate debate by 
some studies specifically including only patients who are deficient in folate a priori and may 
thus thought to be clinically distinct and potentially differentially responsive to folate 
supplementation. (Godfrey et al., 1992) The question of appropriate analysis of differing data 
sets also rages with some studies advocating combing folate results with those of 
methylfolate, (Taylor et al., 2003) and others suggesting they be analysed separately. (Sarris 
et al., 2016) There is also the question of whether it is appropriate to combine differing doses 
as doses range from 0.5mg and 10mg in the randomised controlled trial folate literature. 
(Coppen and Bailey, 2000, Resler et al., 2008) Differing outcome measures of response to 
therapy in depression also lead to issues of “combinability” with some studies using the 
Hamilton Depression Scale (Godfrey et al., 1992) and others the Beck Depression Inventory 
(Bedson et al., 2014) as their primary efficacy measurement.    
Other concerns exist surrounding the incorporation of observational data into systematic 
review and range from asking if it is indeed ever appropriate to do so, to increasing use of 
non-randomised data as an accepted standard. When randomised trials which answer specific 
clinical questions exist within the literature there is often a subsequent total disregard for 
extant observational data. The contrary position is taken in the CANMAT guidelines, which 
acknowledge the presence of a retrospective observational analysis (Ginsberg et al., 2011) 
despite contradictory evidence from randomised controlled trials (Bedson et al., 2014) and 
use this as justification for a positive recommendation for the use of folate and its derivatives 
as monotherapy or an adjunctive treatment in MDD.  
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Systematic reviews are also potentially out of date the moment they are published, with cut 
off dates for study inclusion a seemingly unavoidable limitation. Compounded with this is the 
propensity for some clinicians to look solely for the latest Cochrane review, which may, as in 
the case of folate, be many years out of date. (Taylor et al., 2003) This has the potential to 
lead to concerns regarding cherry picking of literature known to guideline developers 
published subsequent to the latest systematic review, without explicitly conducting a newly 
updated systematic review. Whilst guideline developers may be resource limited in terms of 
time and expertise to conduct systematic reviews for all clinical questions, potential cherry 
picking of newly published literature may lead to inconsistency within and between guidance 
documents. It should also be noted that reviews should be updated in a timely fashion, 
although there is differing consensus on what timescale these updates should occur for 
differing clinical questions. (Garner et al., 2016) The practicalities of conducting a new 
evidence synthesis for each clinical question may outweigh the benefits in certain cases, 
although it should be noted that NICE does conduct a novel systematic review, or in some 
cases update an existent systematic review for each clinical question it poses, although for 
reasons unbeknownst to the authors it has not chosen to subject folate to this process.   
What about small, poorly conducted clinical trials which do not report according to the 
Consolidated Standards of Reporting Trials Group (CONSORT)? (Schulz et al., 2010) Should we 
even include them in systematic review if they score highly on risk of bias quality assessments 
and do they have the potential to skew our interpretation of the results?  
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When the question is that of clinical efficacy of an oral therapy, a randomised controlled trial 
is the most appropriate design and a placebo control the most appropriate comparator within 
ethical constraints. Such trials should, if appropriate, be combined in meta-analysis. We 
would argue all available randomised data should be included, appropriate weight given to it 
in meta-analysis and appropriate weight ascribed it as per quality assessment. Subgroup and 
sensitivity analyses conducted to interrogate potential problems with inconsistency in terms 
of population, intervention, comparison, outcome and risk of bias could then be used as a 
tool to examine potential inconsistency.  
 
GRADE: ‘A Better Way’?  
The Grading of Recommendations, Assessment, Development and Evaluations (GRADE), 
system was developed to address some of the problems outlined above. (GRADE) Historically, 
levels of evidence hierarchy within international guidance have placed emphasis on trial 
design above all else. A systematic review of randomised trials, irrespective of its rigour, 
trumps all other forms of evidence. Issues when ascribing quality of specific outcomes within 
a study to the quality of the overall study are numerous, the classical example being that 
‘blinding’ may be less of a problem when assessing risk of bias in objective compared to 
subjective outcomes. GRADE attempts to address this by rating quality by outcome rather 
than study. The study design remains incorporated into the overall quality rating by 
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establishing a priori a presupposed level of quality that can up or downgraded accordingly 
dependent on how rigorously studies have been conducted. Evidence from Randomised 
Controlled Trials (RCTs) for example starts at the ‘high’ quality level and is downgraded for 
any potential methodological flaw or risk of bias encountered per outcome.  Each outcome is 
thus given a quality rating of ‘high’, ‘moderate’, ‘low’ or ‘very low’ based upon risk of bias, 
inconsistency, indirectness, imprecision, and consideration of other potential sources of bias 
including those arising from funding sources, and from publication bias. Risk of bias is 
established using standardised risk of bias tools and checklists such as the Cochrane Risk of 
bias tool, and rated as ‘no risk of bias’, ‘serious’ risk of bias or ‘very serious’ risk of bias. The 
overall designation of ‘none’, ‘serious’, or ‘very serious’ is aggregated based on the weight 
each individual study contributes data to the outcome in question.  Inconsistency is based on 
measurements of comparability of studies within the meta-analysis and uses a priori specified 
measures of heterogeneity such as the I2 statistic to establish thresholds for ‘no’, ‘serious’ and 
‘very serious’ risk of inconsistency. Imprecision relates to the width of the confidence intervals 
surround a particular outcomes’ result, and their relation to predetermined thresholds of 
results that would be deemed to be clinically significant.  
The GRADE system was primarily developed to assess quality of outcomes in interventional 
studies and therefore problems can arise when attempting to modify this system for data 
from observational studies. The quality rating per outcome begins at ‘low’ quality and can 
subsequently be upgraded or downgraded per individual outcome when using observational 
data. This initial ‘low’ rating is based purely on the study’s observational design and does not 
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take into consideration that observational studies may be the most appropriate study design 
to assess specific outcomes such as risk of longer term adverse event outcomes. (Roberts et 
al., 2016) GRADE has not been used in any of the published meta-analyses regarding folate 
therapy, nor has it been used in any of the international guidance documents discussed 
above. GRADE is a newer method of evidence quality assessment and clinicians may thus 
naturally be dubious about its interpretation compared with the ‘traditional’ level I, II, III etc. 
reported in guidance documents.  Nevertheless, GRADE provides a systematic and replicable 
approach to making judgements about both the quality of assessed evidence and the strength 
of corresponding recommendations. In 2013 the Scottish intercollegiate Guideline Network 
(SIGN) released a statement stating it would transition from using an evidence hierarchy 
approach to a GRADE based system. This decision was taken following analysis of qualitative 
data collected from clinicians, which demonstrated that their current hierarchical evidence 
system was largely ignored or misinterpreted by almost all users of their guidelines. GRADEs 
ability to make ‘strong’ or ‘conditional’ recommendations was seen to be more clinically 
useful. (SIGN) 
 
An example 
We searched Medline, Embase, PsychINFO and CENTRAL from database inception until 1st 
May 2017 for randomised controlled trials. We included trials that evaluated folate or its 
derivatives as monotherapy or to augment antidepressant therapy compared with placebo in 
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patients with unipolar depressive illness. (The search terms were ((*folate* OR folic) AND 
(randomi*) AND (placebo) AND (depressi*))) Two reviewers (ER and BC) independently 
assessed all titles and abstracts for inclusion and assessed included studies for risk of bias 
using the Cochrane Risk of Bias tool. Where agreement could not be reached a third author 
(AY) was consulted. All references were checked for additional citations.  
Quality Assessment 
GRADE was used to assess the quality per outcome. Risk of bias was assessed using the 
Cochrane risk of bias tool. Heterogeneity was considered substantial if I2 > 50% and explained 
using subgroups of the type of medicinal product delivered (folic acid versus methylfolate) 
and the dose. With regards risk of bias if the number of methodological limitations per 
outcome was one given the weight of each study contributed to the outcome the risk of bias 
was defined a serious, if the number of limitations was  two the risk was defined as very 
serious. With regards to inconsistency, if the I2 was >50% and <75% the limitations as per the 
quality assessment by GRADE were deemed serious, if the I2 was ≥75% the risk was defined 
as very serious. With regards to imprecision, if the confidence interval crossed a standardised 
mean difference of magnitude 0.5 from the line of no effect the risk was defined as serious, 
if the confidence interval crossed both 0.5 magnitudes from the line of no effect the risk was 
defined as very serious.   
 14 
We also report the percentage of the total number of studies included in the review assessed 
as low, unclear or high risk for each element of bias assessed by the Cochrane Risk of Bias 
tool. 
 
Statistical Analysis 
Data was extracted at the longest reported study time point. A preferential hierarchy to 
extract treatment effect outcome was ascribed a priori.  The Hamilton rating scale for 
depression (HAMD) (Hamilton, 1960) score was preferentially extracted if reported, followed 
by the Beck Depression Inventory (BDI). (Beck, 1996) Instruments were synthesised into a 
pooled analysis using standardised mean difference and follow up standard deviations (SD) 
missing were estimated by those at baseline. Data were synthesised and weighted inversely 
proportional to the variance with which it estimated that difference and fitted with a random 
effects model. Heterogeneity was assessed using the I2 statistic, if this was >50% subgroups 
were used to explore and explain the heterogeneity. We planned to conduct subgroup 
analyses based on type of medicinal product, either folate or its metabolic derivatives, and 
examining at different clinically utilised dosages. Folate was defined as low dose (<5mg/day) 
or high dose (≥5mg/day). Methylfolate was defined as optimal dose (15mg/day), or 
suboptimal dose (<15mg/day).  All analyses were conducted within Review Manager Version 
5.3. 
Results 
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213 records were identified from the search. We accessed 25 full texts and assessed them for 
eligibility. Six studies were included which represented seven unique RCTs, including a total 
of 966 participants. (Godfrey et al., 1992, Coppen and Bailey, 2000, Bedson et al., 2014, 
Papakostas et al., 2012b, Resler et al., 2008, Sepehrmanesh et al., 2016) A PRISMA diagram 
and a list of excluded studies with reasons for exclusion can be found in the online 
supplementary material. Four trials report on folic acid versus placebo, two at low dose 
(<5mg/day) and two at high dose (≥5mg/day). Three trials report on methylfolate versus 
placebo, two at optimal dose (15mg/day), and one at suboptimal dose (<15mg/day). Table 
one describes the characteristics of included studies. Figure one shows forest plots for each 
comparison. Figure two shows the risk of bias assessment and figure three the GRADE table 
and quality ratings for each outcome. 
Table 1: Included Studies  
Study Country n Population Interventio
n 
Comparison Primary 
Outcom
e 
Godfrey 1990 United 
Kingdom 
24 DSM-III 
major 
depression
; 
Participant
s had a 
red-cell 
folate 
below 
200g/l 
15mg 
Methylfolat
e 
Placebo; Methylfolate therapy 
an adjunct to undefined 
antidepressant treatment 
HAM-D 
17 
Coppen 2000 United 
Kingdom 
12
7 
DSM-III-R 
major 
depression 
0.5mg 
Folate 
Placebo; Folate therapy as an 
adjunct to fluoxetine 20mg PO 
once daily 
HAM-D 
17 
Resler 2008 Venezuel
a 
27 DSM-IV 
major 
10mg 
Folate 
Placebo; Folate therapy as an 
adjunct to fluoxetine 20mg PO 
once daily 
HAM-D 
17 
 16 
depressive 
episode 
Bedson 2014 United 
Kingdom 
47
5 
Moderate 
to severe 
depressive 
symptoms 
determine
d by trial 
psychiatris
t 
5mg Folate Placebo; Folate therapy as an 
adjunct to any antidepressant 
at adequate dose and duration 
BDI-II 
Papakostas 
2014 (I) 
United 
States of 
America 
14
8 
DSM-IV 
major 
depressive 
disorder 
7.5mg for 
30 days 
increasing 
to 15mg 
Methylfolat
e 30 days 
Group 1: Placebo for 30 days 
followed by placebo and 7.5mg 
Methlyfolate for 30 days; 
Group 2: Placebo for 60 days; 
Methylfolate therapy as an 
adjunct to 
fluoxetine/paroxetine/citalopra
m ≥20 mg/day, escitalopram 
≥10 mg/day, or sertraline ≥50 
mg/day 
HAM-D 
17 
Papakostas 
2014 (II) 
United 
States of 
America 
75 DSM-IV 
major 
depressive 
disorder 
15mg 
Methylfolat
e for 60 
days 
Group 1: Placebo for 30 days 
followed by placebo and 15mg 
Methylfolate for 30 days; 
Group 2: Placebo for 60 days; 
Methylfolate therapy as an 
adjunct to 
fluoxetine/paroxetine/citalopra
m ≥20 mg/day, escitalopram 
≥10 mg/day, or sertraline ≥50 
mg/day 
HAM-D 
17 
Sepehrmanes
h 2016 
Iran 90 “Depresse
d 
according 
to DSM-IV-
R” 
2.5mg 
Folate 
Placebo; Folate therapy as an 
adjunct to citalopram 20mg PO 
once daily 
BDI-II 
 
Effects of folate and its derivatives on depression 
No trials report on folate or methylfolate versus placebo as a monotherapeutic option in 
unipolar depressive disorders.  
When examining all doses of both folate or methylfolate compared with placebo seven 
randomised controlled trials of 904 participants demonstrate an effect size of -0.37 (95%CI: -
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0.72, -0.01; P=0.04; I2=79%; Figure 1a), which is of VERY LOW quality, and included severe 
heterogeneity meaning that the findings may change on the basis of further studies, and offer 
only limited evidence of a clinically useful effect.  
When examining all doses of folate alone compared with placebo, four randomised controlled 
trials of 657 participants demonstrate an effect size of -0.40 (95%CI: -0.88, 0.08; P=0.1; 
I2=83%; Figure 1b), which is of VERY LOW quality, and included severe heterogeneity meaning 
that the findings may change on the basis of further studies and offering limited evidence of 
a clinically useful effect.  When this is restricted to doses of ≥5mg/day two trials of 476 
participants demonstrate an effect size of -0.24 (95%CI: -1.03, 0.56; P=0.56; I2=76%; Figure 
1d), of VERY LOW quality, again highlighting severe heterogeneity and no evidence of an 
effect. When restricted to doses of <5mg/day two trials of 190 participants demonstrate an 
effect size of -0.57 (95%CI: -0.91, -0.23; P<0.001; I2=25%; Figure 1d) of LOW quality evidence, 
with low heterogeneity, offering evidence of a clinically useful effect.   
When examining all doses of methylfolate alone compared with placebo, three randomised 
controlled trials of 247 participants demonstrate an effect size of -0.34 (95% CI: -1.08, 0.40; 
P=0.37; I2=81%; Figure 1c), which is of VERY LOW quality, highlighting severe heterogeneity 
and no evidence of an effect. When this is restricted to a dose of 15mg/day methylfolate two 
trials of 99 participants demonstrate an effect size of -0.74 (95%CI: -1.19, -0.29; P=0.002; 
I2=2%; Figure 1d), which is of LOW quality, with low heterogeneity, offering evidence of a 
clinically useful effect. When this is restricted to a suboptimal dose of <15mg/day 
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methylfolate one trial of 148 participants demonstrate an effect size of 0.19 (95%: -0.18, 0.57; 
P=0.32; Figure 1d) of LOW quality evidence, with no evidence of an effect.   
 
Figure 1: Forest Plots 
 
a) All doses of folate or its derivatives compared with placebo  
 
b) All doses of only folate compared with placebo 
 
c) All doses of only methylfolate compared with placebo 
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d) Folic acid low dose (<5mg/day), and high dose (≥5mg/day), and methylfolate optimal-dose 
(15mg/day) and suboptimal dose (<15mg/day)  
 
 
Figure 2: Risk of Bias  
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The figure reports the percentage of the total number of studies included in the review 
assessed as low, unclear or high risk of bias for each element of bias assessed by the Cochrane 
Risk of Bias tool. 
 
Figure 3: GRADE table 
Quality assessment No of patients Effect 
Quality 
 No of 
studies 
Design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Folate or 
Methylfolate 
Placebo 
Effect Size 
(95% CI) 
 
Efficacy – Overall (Bedson 2013, Coppen 2000, Godfrey 1990, Papakostas (I) 2014, Papakostas (II) 2014, Resler 2008, 
Sepehrmanesh 2016) 
7 RCT Serious Very serious None Serious None 399 505 -0.37 
[-0.72, -0.01] 
VERY 
LOW 
Efficacy – Folate All Doses (Bedson 2013, Coppen 2000, Resler 2008 Sepehrmanesh 2016) 
4 RCT Serious Very Serious None Serious None 331 326 -0.40 
[-0.88, 0.08] 
VERY 
LOW 
Efficacy – Folate High Dose ≥5mg/day  (Bedson 2013, Resler 2008) 
2 RCT None Very Serious None Very 
Serious 
None 237 230 -0.24  
[-1.03, 0.56] 
VERY 
LOW 
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Efficacy -  Folate Low dose <5mg/day (Coppen 2000, Sephermanesh 2016) 
2 RCT Serious None None Serious None 94 96 -0.57  
[-0.91, -0.23] 
LOW 
Efficacy – Methylfolate All Doses (Godfrey 1990, Papakostas (I) 2014, Papakostas (II) 2014) 
3 RCT Serious Very Serious None Serious None 68 179 -0.34 
[-1.08, 0.40] 
VERY 
LOW 
Efficacy – Methylfolate Suboptimal Dose <15mg /day  (Papakostas (I) 2014) 
1 RCT Serious  None None Serious None 36 112 0.19  
[-0.18, 0.57] 
LOW 
Efficacy – Methylfolate Optimal dose 15mg/day (Godfrey 1990, Papakostas (II) 2014) 
2 RCT Serious None None Serious None 32 67 -0.74  
[-1.19, -0.29] 
LOW 
 
Recommendations  
Although we fully appreciate this meta-analysis has the potential to be out of date the 
moment this manuscript is accepted for publication, our recommendations based on 
current evidence available would be: 
1. Do not offer either folate or methylfolate as monotherapy in patients with major 
depressive disorder. 
2. Consider folate at a dose of <5mg/day or methylfolate at a dose of 15mg/day as an 
adjunct to SSRI therapy in patients with major depressive disorder. This 
recommendation is based on low quality evidence as assessed by GRADE. 
 
Our approach regarding the use of folate and its derivatives in the treatment of unipolar 
depressive disorders uses the most up to date randomised placebo-controlled evidence to 
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generate recommendations. We included all trial data and examined anticipated 
heterogeneity by using subgroup analyses to explore potential variation attributable to 
prespecified clinical variables, including the type of folate formulation delivered and the 
dosage. We used a clear GRADE system to evaluate each outcomes quality, demonstrating 
that all outcomes are likely to be impacted by any subsequent publication of further 
research on this topic.  
Whilst previous guidelines on the treatment of unipolar depression have either avoided this 
topic entirely (NICE, WFSBP) (NICE, 2016, Bauer et al., 2013) or made recommendations on 
the basis of a cherry picked single trials (BAP), (Cleare et al., 2015) a non systematically 
reviewed evidence base (CANMAT), (Patten, 2016) or on perceived quality of evidence 
related solely to trial design (BAP, CANMAT) (Cleare et al., 2015, Patten, 2016) these 
recommendations are the first to provide rigorous recommendations examining the 
formulation and dose of folate and its derivatives, and aim to generate clinically useful 
recommendations. 
We invite discussion of the above review and its recommendations.  
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